sacituzumab govitecan
gilead sciences
['tropics-02', 'tnbc']
#asco2022 rugo tropics-02. median pfs for sac vs tpc was 5.5 vs 4 mo, statistically significant but clinically unimpressive. os 13.9 vs 12.3 mo, not yet mature. my take: not a game changer. keep saci for tnbc.
Professor of Medicine, Stanford University; breast cancer doc